T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04035-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Thikra Majid Muhammed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biology Department, College of Education for Pure Sciences, University of Anbar, Anbar, Iraq. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Lymphocytes, Tumor-Infiltrating, Immunotherapy, Adoptive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 134 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related death worldwide. The primary therapies for HCC are liver transplantation, hepatic tumor excision, radiofrequency ablation, and molecular-targeted medicines. An unfavorable prognosis marks HCC and has limited pharmacological response in therapeutic studies. The tumor immune microenvironment (TME) imposes significant selection pressure on HCC, resulting in its evolution and recurrence after various treatments. As the principal cellular constituents of tumor-infiltrating lymphocytes (TILs), T cells have shown both anti-tumor and protumor actions in HCC. T cell-mediated immune responses are pivotal in cancer monitoring and elimination. TILs are recognized for their critical involvement in the progression, prognosis, and immunotherapeutic management of HCC. Foxp3 + , CD8 + , CD3 + , and CD4 + T cells are the extensively researched subtypes of TILs. This article examines the functions and processes of several subtypes of TILs in HCC. Emerging T cell-based therapies, including TILs and chimeric antigen receptor (CAR)-T cell therapy, have shown tumor regression in several clinical and preclinical studies. Herein, it also delves into the existing T cell-based immunotherapies in HCC, with emphasis on TILs and CAR-T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biology Department, College of Education for Pure Sciences, University of Anbar, Anbar, Iraq.
- Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-Maarif, Anbar, Iraq. saad.a.j.anbar@gmail.com.
- Department of Medical Analysis, Medical Laboratory Technique College, The Islamic University, Najaf, Iraq.
- Department of Medical Analysis, Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
- Department of Medical Analysis, Medical Laboratory Technique College, The Islamic University of Babylon, Babylon, Iraq.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Zitieren
APA
Muhammed, T. M., Jasim, S. A., Zwamel, A. H., Rab, S. O., Ballal, S., Singh, A., Nanda, A., Ray, S., Hjazi, A., & Yasin, H. A. (2025). T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04035-9
Vancouver
Muhammed TM, Jasim SA, Zwamel AH, Rab SO, Ballal S, Singh A, et al. T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04035-9
BibTeX
@article{Muhammed2025,
author = {Muhammed, Thikra Majid and Jasim, Saade Abdalkareem and Zwamel, Ahmed Hussein and Rab, Safia Obaidur and Ballal, Suhas and Singh, Abhayveer and Nanda, Anima and Ray, Subhashree and Hjazi, Ahmed and Yasin, Hatif Abdulrazaq},
title = {T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04035-9}
}
EUVIMED